IAI Try MCB online
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
IAI.00731-07v1
75/11/5223    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tomimori, K.
Right arrow Articles by Mori, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tomimori, K.
Right arrow Articles by Mori, N.
Infection and Immunity, November 2007, p. 5223-5232, Vol. 75, No. 11
0019-9567/07/$08.00+0     doi:10.1128/IAI.00731-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Helicobacter pylori Induces CCL20 Expression{triangledown}

Koh Tomimori,1,2 Eriko Uema,1,2 Hiromitsu Teruya,1,2 Chie Ishikawa,1,3 Taeko Okudaira,1,4 Masachika Senba,5 Kazuo Yamamoto,6 Toshifumi Matsuyama,6 Fukunori Kinjo,7 Jiro Fujita,2 and Naoki Mori1*

Divisions of Molecular Virology and Oncology,1 Control and Prevention of Infectious Diseases, Graduate School of Medicine,2 Divisions of Child Health and Welfare,3 Endocrinology and Metabolism, Faculty of Medicine,4 Department of Endoscopy, University Hospital, University of the Ryukyus, Nishihara, Okinawa 903-0215, Japan,7 Department of Pathology, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan,5 Division of Cytokine Signaling, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8523, Japan6

Received 30 May 2007/ Returned for modification 31 July 2007/ Accepted 16 August 2007


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
CCL20 attracts immature dendritic cells and memory T cells and plays a role on mucosal surfaces in inflammation. However, whether Helicobacter pylori infection induces CCL20 in human gastric epithelial cells remains to be determined. The aim of this study was to analyze the molecular mechanism of H. pylori-induced CCL20 expression. Expression of CCL20 mRNA was assessed by reverse transcription-PCR. Five normal and five H. pylori-infected gastric tissue samples were stained immunohistochemically for CCL20. A luciferase assay was used to monitor activation of the CCL20 gene promoter, and an electrophoretic mobility shift assay was used to explore the binding of transcription factors to this promoter. The CCL20 expression in epithelial cells of H. pylori-positive tissues was higher than that in H. pylori-negative tissues. H. pylori induced CCL20 expression in gastric epithelial cell lines, and the induction was dependent on an intact cag pathogenicity island. Activation of the CCL20 promoter by H. pylori occurred through the action of NF-{kappa}B. Transfection of I{kappa}B kinase and NF-{kappa}B-inducing kinase dominant negative mutants inhibited H. pylori-mediated activation of CCL20. Treatment with an inhibitor of Hsp90 suppressed H. pylori-induced CCL20 mRNA due to deactivation of NF-{kappa}B. Collectively, these results suggest that H. pylori activates NF-{kappa}B through an intracellular signaling pathway that involves I{kappa}B kinase and NF-{kappa}B-inducing kinase, leading to CCL20 gene transcription, and that Hsp90 is a crucial regulator of H. pylori-induced CCL20 expression, presumably contributing to the immune response in H. pylori.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Helicobacter pylori plays an important role in the pathogenesis of human gastric disease. In 10 to 20% of infected individuals, the H. pylori-induced chronic gastric inflammation progresses to peptic ulcers, gastric cancer, or gastric mucosa-associated lymphoid tissue lymphoma (22, 23, 50). Bacterial, environmental, and host genetic factors may affect the progress and outcome of gastric disease. One such factor that is responsible for severe disease is the virulence of individual H. pylori strains. Several virulence factors have been described, and these factors include the presence of a vacuolating cytotoxin (vacA) and a cag pathogenicity island (PAI) (12, 41, 43). H. pylori strains that carry cag PAI genes, called type I strains, are very prevalent in patients with peptic ulcers and gastric cancer (4, 10, 13).

There is abundant evidence that T lymphocytes play a pivotal role in the pathogenesis of H. pylori-induced chronic gastric inflammation (46). This pathological state is considered a Th1-mediated process characterized by an increase in gamma interferon, which is implicated in perpetuating the inflammatory changes that lead to disease (14, 32). Several trafficking mechanisms are involved in the selective recruitment of T lymphocytes in the mucosa, such as selectins, the immunoglobulin superfamily, {alpha}4ß7, {alpha}4ß1, and {alpha}Eß7 integrins, and chemokines (29).

Elucidation of a T-lymphocyte response is currently believed to require interaction with professional antigen-presenting cells (e.g., dendritic cells [DCs]) (3). Because the normal gastric mucosa has no mucosa-associated lymphoid system, very little is known about the role of DCs in the mucosal immune system of the stomach. However, several groups have shown that human DCs are activated and secrete cytokines when they are cultured in the presence of H. pylori (20, 33). A recent study also demonstrated the recruitment of DCs to the gastric mucosa after H. pylori infection in mice (30).

Chemokines acting through seven transmembrane-spanning G-protein-coupled receptors are believed to be critical in the migration of lymphocytes and DCs out of blood vessels into peripheral tissue and secondary lymphoid organs (2, 37). In the multistep model of immune cell recruitment, various adhesion molecules, including selectins, mediate transient (rolling) interactions with endothelial cells, whereas chemokines have been shown to induce firm arrest via integrins in vitro (9) and in vivo (8, 17). CCL20 (also known as macrophage inflammatory protein 3{alpha} [47], liver and activation-regulated chemokine [21], and Exodus [24]) is one of a small number of chemokines that have been demonstrated to induce arrest of lymphocytes under flow conditions (9, 17). The receptor for CCL20, CCR6, is restricted to CD45RO+ memory T cells (34). Furthermore, CCL20 has recently been identified as the chemokine that recruits immature CD11b+ myeloid DCs to mucosal surfaces, allowing their antigen uptake and further migration toward secondary lymphoid organs (15, 16, 27). Because CCR6 mediates DC localization, lymphocyte homeostasis, and immune responses in mucosal tissue (11) and CCL20 preferentially attracts memory T cells (34), CCL20 may play a role in gastric inflammation. This capacity of CCL20 to recruit immature DCs (capable of H. pylori antigen uptake and thus potentially promoting further T-cell activation) and T cells with homing properties for the gastric mucosa prompted us to investigate the expression of CCL20 in human H. pylori-induced gastritis.

The present study was designed to evaluate the effect of H. pylori on the expression of CCL20 in gastric epithelial cells both in vitro and in vivo and to study the role of H. pylori virulence factors in any such effect. We detected the expression of CCL20 in human gastric mucosa of patients infected with H. pylori. We found that H. pylori activated CCL20 gene expression in gastric epithelial cells. We also showed that the NF-{kappa}B element is essential for H. pylori-induced activation of CCL20 gene expression. This was related to the expression of the cag PAI responsible for cytokine/chemokine production.

The 90-kDa heat shock protein, Hsp90, is a major molecular chaperone and appears to have particular significance for cellular regulatory processes. Recent studies revealed that the majority of client proteins of Hsp90 are protein kinases or transcription factors that play important roles in cellular carcinogenesis (45). Several groups have also documented that Hsp90 plays a critical role in the inflammatory response, and the presence of its inhibitor resulted in a reduced immune response, as indicated by a decrease in proinflammatory mediator production (7, 59). Furthermore, a recent study indicated that I{kappa}B kinase {alpha} (IKK{alpha}) and IKKß are clients of Hsp90 (6). Finally, we demonstrated that Hsp90 acted as a crucial regulator in H. pylori-induced CCL20 expression. We postulate that CCL20 plays a role in the development of gastric inflammation associated with H. pylori.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Antibodies and reagents. Goat polyclonal antibody to CCL20 was purchased from R&D Systems (Minneapolis, MN). Rabbit polyclonal antibodies to I{kappa}B{alpha} and NF-{kappa}B subunits p50, p65, c-Rel, p52, and RelB were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal antibodies to Hsp90 and actin were purchased from BD Transduction Laboratories (San Jose, CA) and NeoMarkers (Fremont, CA), respectively. Mouse monoclonal antibody to phospho-I{kappa}B{alpha} (Ser-32 and Ser-36) and rabbit polyclonal antibodies to IKK{alpha} and IKKß were purchased from Cell Signaling Technology (Beverly, MA). Rabbit polyclonal antibody to IKK{gamma} was purchased from Sigma-Aldrich (St. Louis, MO). N-acetyl-L-leucyl-L-leucyl-L-norleucinal (LLnL) and Bay 11-7082 were purchased from Sigma-Aldrich and Calbiochem (La Jolla, CA), respectively. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) was purchased from Alomone Labs (Jerusalem, Israel).

Bacterial strains. H. pylori ATCC 49503 (American Type Culture Collection, Rockville, MD) was used in most experiments described in this study. Other clinical strains (OHPC0001, OHPC0002, and OHPC0003), isolated from patients with chronic gastritis, were kind gifts from T. Kitahora (Ohkura Hospital, Tokyo, Japan). An isogenic H. pylori mutant lacking the cag PAI (51) was also studied together with its parental wild-type strain (26695). The presence of the cag PAI and vacA in these strains was determined previously by PCR using specific sets of primers (1, 53). H. pylori strains were plated on blood agar plates and incubated at 37°C for 3 days under microaerophilic conditions. Using cotton swabs, bacteria harvested from the plates were suspended in 200 ml of brain heart infusion broth containing 10% fetal bovine serum (FBS) and then cultured in the liquid medium at 37°C for 2 days in a controlled microaerophilic environment. Bacteria were harvested from the broth culture by centrifugation and then resuspended at the concentrations indicated below in antibiotic-free medium. Cultured bacteria reached a density of 3 x 109 CFU/ml. All procedures were performed with the approval of the appropriate institutional biosafety review committees and in compliance with their guidelines for biohazards.

Cell culture. Human gastric epithelial cells (MKN45 and MKN28) were maintained in RPMI 1640 medium containing 10% FBS, 100 U/ml penicillin G, and 100 µg/ml streptomycin. On the day of the experiment, cells were fed with fresh serum- and antibiotic-free medium and cocultured with H. pylori at a final concentration of 107 CFU/ml for the time intervals indicated below.

Tissue samples. Five histopathologically normal stomach biopsy specimens and stomach biopsy specimens from five patients with H. pylori gastritis were used for reverse transcription (RT)-PCR analysis and examined histopathologically for CCL20. The presence of H. pylori infection was determined by culturing, serological analysis (with anti-H. pylori immunoglobulin G antibody), a rapid urease test, and histological visualization with Giemsa staining. Patients with H. pylori gastritis showed polymorphonuclear neutrophil infiltration in the gastric epithelium in conjunction with the presence of bacterial forms, consistent with H. pylori infection. All samples were obtained after informed consent was received from the subjects.

RT-PCR. Total cellular RNA was extracted with Trizol (Invitrogen, Carlsbad, CA) according to the protocol provided by the manufacturer. First-strand cDNA was synthesized from 1 µg total cellular RNA using an RNA PCR kit (Takara Bio Inc., Otsu, Japan) with random primers. Thereafter, cDNA was amplified using 30 and 28 cycles for CCL20 and ß-actin, respectively. The specific primers used were as follows: for CCL20, forward primer 5'-ATGTGCTGTACCAAGAGTTTGC-3' and reverse primer 5'-CCAATTCCATTCCAGAAAAGCC-3'; and for ß-actin, forward primer 5'-GTGGGGCGCCCCAGGCACCA-3' and reverse primer 5'-CTCCTTAATGTCACGCACGATTTC-3'. The product sizes were 320 bp for CCL20 and 548 bp for ß-actin. The thermocycling conditions for the targets were as follows: 94°C for 60 s for CCL20 and for 30 s for ß-actin, 60°C for 60 s for CCL20 and for 30 s for ß-actin, and 72°C for 60 s for CCL20 and for 90 s for ß-actin. The PCR products were fractionated on 2% agarose gels and visualized by ethidium bromide staining.

Plasmids. The I{kappa}B{alpha}{Delta}N and I{kappa}Bß{Delta}N dominant negative mutants (kindly provided by D. W. Ballard, Vanderbilt University School of Medicine, Nashville, TN) are I{kappa}B{alpha} and I{kappa}Bß deletion mutants lacking the NH2-terminal 36 and 23 amino acids, respectively (5, 38). The IKK{alpha} dominant negative mutant IKK{alpha} (K44M), the IKKß dominant negative mutant IKKß (K44A), and the IKK{gamma} dominant negative mutant IKK{gamma} (1-305), as well as the NF-{kappa}B-inducing kinase (NIK) dominant negative mutant NIK (KK429/430AA), have been described previously (19, 25). Reporter plasmid {kappa}B-LUC is a luciferase expression plasmid controlled by five tandem repeats of the NF-{kappa}B binding sequences of the interleukin-2 (IL-2) receptor (IL-2R) {alpha}-chain gene. The CCL20 promoter pGL2 luciferase reporter plasmid containing the wild-type sequence (position –874 to position 58) or the NF-{kappa}B site mutant was used to map H. pylori-responsive regions (26).

Transfection and luciferase assay. A total of 2 x 106 MKN45 cells were transfected with 1 µg of the appropriate reporter and 5 µg of effector plasmids using Lipofectamine (Invitrogen). After 24 h, H. pylori was added and incubated for 6 h. The ratio of bacteria to cells was 20:1. Preliminary studies with MKN45 cells using various numbers of H. pylori bacteria indicated that a higher concentration of bacteria (final concentration, 500 organisms/cell) induced the death of epithelial cells, as determined by morphological analysis. The cells were washed in phosphate-buffered saline (PBS) and lysed in reporter lysis buffer (Promega, Madison, WI). Lysates were assayed for reporter gene activity with the dual luciferase assay system (Promega). Luciferase activities were normalized relative to the Renilla luciferase activity from phRL-TK.

Preparation of nuclear extracts and EMSA. NF-{kappa}B binding activity with the NF-{kappa}B element was examined by an electrophoretic mobility shift assay (EMSA) as described previously (40). To examine the specificity of the NF-{kappa}B element probe, we preincubated unlabeled competitor oligonucleotides with nuclear extracts for 15 min before incubation with the probe. The probe or competitors used were prepared by annealing the sense and antisense synthetic oligonucleotides as follows: for the NF-{kappa}B element of the CCL20 gene, 5'-GATCGATCAATGGGGAAAACCCCATGTG-3'; for the NF-{kappa}B element of the IL-2R {alpha}-chain gene, 5'-GATCCGGCAGGGGAATCTCCCTCTC-3'; and for the AP-1 element of the IL-8 gene, 5'-GATCGTGATGACTCAGGTT-3'. The oligonucleotide 5'-GATCTGTCGAATGCAAATCACTAGAA-3', containing the consensus sequence of the octamer binding motif, was used to identify specific binding of the transcription factor Oct-1. The underlined sequences are the NF-{kappa}B, AP-1, and Oct-1 binding sites. To identify NF-{kappa}B proteins in the DNA-protein complex shown by the EMSA, we used antibodies specific for various NF-{kappa}B family proteins, including p50, p65, c-Rel, p52, and RelB, to elicit supershift DNA-protein complex formation. These antibodies were incubated with the nuclear extracts for 45 min at room temperature before incubation with radiolabeled probe.

Western blot analysis. Cells were lysed in a buffer containing 62.5 mM Tris-HCl (pH 6.8), 2% sodium dodecyl sulfate, 10% glycerol, 6% 2-mercaptoethanol, and 0.01% bromophenol blue. Equal amounts of protein (20 µg) were subjected to electrophoresis on sodium dodecyl sulfate-polyacrylamide gels, followed by transfer to a polyvinylidene difluoride membrane and sequential probing with the specific antibodies. The bands were visualized with an enhanced chemiluminescence kit (Amersham Biosciences, Piscataway, NJ).

CCL20 measurement. The CCL20 content in the culture supernatants was measured by an enzyme-linked immunosorbent assay (ELISA) (R&D Systems). MKN45 and MKN28 cells were cultured in RPMI 1640 supplemented with 10% FBS in 24-well plates. Subconfluent monolayers of cells were cocultured with H. pylori for 24 h. The supernatants were then collected after centrifugation to remove bacteria and stored at –80°C until they were assayed for CCL20 by ELISA. The concentration of CCL20 was determined using a standard curve obtained with recombinant CCL20.

Immunohistochemical analysis. Serial sections were deparaffinized in xylene and dehydrated using a graded ethanol series. For better detection, sections were pretreated with ready-to-use proteinase K (Dako, Inc., Carpinteria, CA) for 20 min at 37°C. This procedure increased the number of antigenic sites available for binding by the antibody. In the next step, the tissues were placed in 3% hydrogen peroxide and absolute methanol for 5 min to reduce endogenous peroxidase activity, followed by washing in PBS. The tissue sections were incubated with goat anti-human CCL20 polyclonal antibody (diluted 1:250) or a control mouse immunoglobulin G for 3 h at 37°C. After washing with PBS, the sections were covered with EnVision plus (Dako, Santa Barbara, CA) for 40 min at 37°C and washed in PBS. Antigenic sites bound by the antibody were identified by reacting the sections with a mixture of 0.05% 3,3'-diaminobenzidine tetrahydrochloride in 50 mM Tris-HCl buffer and 0.01% hydrogen peroxide for 7 min. Sections were then counterstained with methyl green for 10 min, hydrated in ethanol, cleaned in xylene, and mounted.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
High expression levels of CCL20 in gastric mucosa of patients with H. pylori gastritis. RT-PCR showed the presence of CCL20 transcripts in the specimens from all five patients with H. pylori gastritis (Fig. 1A). Analysis of H. pylori-negative control specimens showed very low or undetectable levels of CCL20 mRNA.


Figure 1
View larger version (49K):
[in this window]
[in a new window]

  		FIG. 1. Expression of CCL20 in H. pylori-infected gastric mucosa. (A) RT-PCR analysis of CCL20 in human gastric tissues. Lanes 1 to 5, normal mucosa; lanes 6 to 10, H. pylori-positive gastritis; lane M, markers. ß-Actin expression served as a control. Representative results of three similar experiments are shown. (B to E) Immunohistochemical detection of CCL20 in tissues of patients with H. pylori-positive gastritis. The serial sections of gastric biopsy specimens were stained with goat polyclonal antibody to CCL20. Sections were counterstained with methyl green. (B and C) Representative examples of normal mucosa. (D and E) Representative examples of mucosa from patients with H. pylori-positive gastritis. Note the positive staining for CCL20 in the epithelial cells of the mucosa from patients with H. pylori-positive gastritis. Original magnification, x400.

 
Immunohistochemical studies. We also investigated the presence of CCL20 protein in patients with H. pylori-positive gastric diseases and determined its cellular source. For this purpose, we immunostained H. pylori-positive gastritis tissues (n = 2). CCL20 staining was detected exclusively in the mucosal epithelial cells of specimens from patients with H. pylori-positive gastritis (Fig. 1D and E). In contrast, CCL20 staining was faint in the normal mucosa (Fig. 1B and C).

H. pylori increases steady-state CCL20 mRNA levels in gastric epithelial cells. Using RT-PCR, we next examined whether coculture of two gastric epithelial cell lines, MKN45 and MKN28, with H. pylori led to induction of CCL20 mRNA. Coculture with H. pylori significantly enhanced the steady-state levels of CCL20 mRNA in both cell lines (Fig. 2A). CCL20 transcript levels clearly increased 1 h after addition of H. pylori to the MKN45 and MKN28 cells; peak levels were reached at 6 h, but the levels were lower at 24 h after cocultivation (Fig. 2A). Supernatants derived from H. pylori cultures failed to induce CCL20 mRNA expression in MKN45 cells (Fig. 2B). Moreover, neither heat-killed bacteria nor live bacteria, separated by a permeable membrane, induced CCL20 mRNA expression in MKN45 cells (data not shown). These results suggest that interaction with live H. pylori itself, rather than products secreted by these bacteria, upregulates the steady-state levels of CCL20 mRNA. In the next step, we examined whether CCL20 was secreted into the culture media of MKN45 and MKN28 cells cocultured with H. pylori. ELISA indicated that CCL20 was secreted into the media of MKN45 and MKN28 cells cocultured with H. pylori over a 24-h period and that its concentration was dependent on the density of H. pylori (Fig. 3).


Figure 2
View larger version (40K):
[in this window]
[in a new window]

  		FIG. 2. H. pylori-induced CCL20 mRNA expression in gastric epithelial cells. (A) Dynamics of H. pylori-induced CCL20 mRNA expression. Total RNA was extracted from MKN45 and MKN28 cells infected with H. pylori ATCC 49503 for the indicated times and used for RT-PCR. The bacterium-to-cell ratio was 20:1. (B) cag PAI-positive and cag PAI-negative H. pylori strains differ in the ability to induce CCL20 expression. (C) cag PAI of H. pylori is required for induction of CCL20 expression in MNK45 cells. Total RNA was extracted from the cells infected with H. pylori for 6 h and used for RT-PCR. ß-Actin expression served as a control. Representative results of three similar experiments in each panel are shown. Lane M contained markers. WT, wild type.

 

Figure 3
View larger version (18K):
[in this window]
[in a new window]

  		FIG. 3. Increased secretion of CCL20 into the supernatants of MKN45 and MKN28 cultures in response to H. pylori infection at 24 h. Cells were infected with various densities of H. pylori ATCC 49503. CCL20 concentrations in the supernatants were determined by ELISA. The data are means ± standard deviations of three experiments.

 
H. pylori-induced CCL20 mRNA expression is strain dependent. Because recent studies indicated that expression of multiple genes in the cag PAI is necessary for cytokine production by gastric epithelial cells in vitro (10, 52), we examined the abilities of various H. pylori strains possessing or lacking the cag PAI to induce CCL20 mRNA expression. Infection with H. pylori strains ATCC 49503, OHPC0001, and OHPC0003, which contain the entire cag PAI (53), led to increased CCL20 mRNA levels in MKN45 cells (Fig. 2B). On the other hand, strain OHPC0002, which lacks the cag PAI (53), failed to induce CCL20 mRNA expression (Fig. 2B). The ability of H. pylori to induce CCL20 mRNA expression was independent of the vacA locus, because all bacterial isolates used in this experiment had this gene (Fig. 2B) (1). Furthermore, strain OHPC0001 induced CCL20 mRNA expression despite the absence of vacuolating cytotoxic activity (1). To determine whether the observed difference in CCL20 mRNA expression was specific to the cag PAI, we next examined a wild-type cag PAI-positive H. pylori strain (26695) and an isogenic cag PAI mutant ({Delta}cag PAI). As expected, stimulation with wild-type strain 26695 induced CCL20 mRNA expression in MKN45 and MKN28 cells, while the isogenic mutant that lacked expression of the cag PAI did not induce expression (Fig. 2C). These results suggest that the H. pylori cag PAI plays an important role in the induction of CCL20 mRNA expression.

H. pylori regulates CCL20 gene transcription. In the next series of experiments, we investigated whether H. pylori-mediated upregulation of CCL20 gene expression could directly enhance the activity of its promoter. MKN45 cells were transiently transfected with a reporter gene construct containing the segment from position –874 to position 58 of the CCL20 upstream regulatory sequences. Coculture of H. pylori resulted in a dose-dependent increase in the activity of this CCL20-driven reporter construct (Fig. 4A). We further investigated the involvement of the cag PAI in the induction of CCL20 promoter activity in MKN45 cells. Wild-type strain 26695 increased CCL20-driven reporter gene activity, but activation of this reporter was not observed with the isogenic mutant {Delta}cag PAI (Fig. 4B). Therefore, the cag PAI appears to be required for activation of the CCL20 promoter.


Figure 4
View larger version (15K):
[in this window]
[in a new window]

  		FIG. 4. H. pylori infection activates the CCL20 promoter in gastric epithelial cells. (A) H. pylori infection increased CCL20 promoter activity in a dose-dependent fashion. Either pGL2-CCL20 or pGL2 (promoterless luciferase vector) was transfected into MKN45 cells, and the cells were subsequently infected with H. pylori ATCC 49503 for 6 h. The activities are expressed relative to that of cells transfected with pGL2-CCL20 without further treatment, which was defined as 1. (B) cag PAI is required for induction of CCL20 promoter activity. pGL2-CCL20, pGL2, or {kappa}B-LUC was transfected into MKN45 cells, and the cells were subsequently infected with wild-type strain 26695 (WT) or the isogenic mutant {Delta}cag PAI ({Delta}cag) for 6 h. The bacterium-to-cell ratio was 20:1. The activities are expressed relative to that of cells transfected with pGL2-CCL20 without further treatment, which was defined as 1. The data are means ± standard deviations of three independent experiments.

 
NF-{kappa}B is essential for activation of the CCL20 promoter by H. pylori infection. The NF-{kappa}B signaling pathway is activated in epithelial cells infected with cag PAI-positive H. pylori but not in cells infected with cag PAI-negative strains of H. pylori (18, 35, 49). Indeed, wild-type strain 26695 increased transcription of the NF-{kappa}B-dependent reporter gene ({kappa}B-LUC), while the isogenic cag PAI mutant did not (Fig. 4B). To test the relative contribution of the NF-{kappa}B binding site to H. pylori-mediated activation of CCL20, the plasmid with point mutations in this site of the CCL20 promoter was transfected (Fig. 5). Mutation of the NF-{kappa}B binding site (CCL20/{kappa}BM) reduced H. pylori-mediated activation of this reporter construct. Therefore, the NF-{kappa}B binding site contributes to activation of the CCL20 promoter induced by H. pylori infection.


Figure 5
View larger version (16K):
[in this window]
[in a new window]

  		FIG. 5. H. pylori activates the CCL20 promoter through the NF-{kappa}B binding site. (A) Schematic diagram of the CCL20 reporter constructs containing the wild-type (pGL2-CCL20) and mutant (pGL2-CCL20/{kappa}BM) NF-{kappa}B sites. Underlined letters indicate substituted base pairs. (B) NF-{kappa}B element in the CCL20 promoter is critical for H. pylori-induced activity. Either pGL2-CCL20 or pGL2-CCL20/{kappa}BM was transfected into MKN45 cells, and the cells were subsequently infected with H. pylori ATCC 49503 for 6 h. The bacterium-to-cell ratio was 20:1. The activities are expressed relative to that of cells transfected with pGL2-CCL20 without further treatment, which was defined as 1. The data are means ± standard deviations of three independent experiments. WT, wild type.

 
H. pylori infection of gastric epithelial cells induces binding of NF-{kappa}B family proteins to the NF-{kappa}B element of the CCL20 promoter. Because the mutational analysis of the CCL20 promoter indicated that H. pylori infection activated transcription through the NF-{kappa}B site, it was important to identify the nuclear factors that bind to this site. The NF-{kappa}B sequence derived from the CCL20 promoter was used as a probe in an EMSA. MKN45 and MKN28 cells were infected with H. pylori at different times after challenge, and nuclear protein extracts were prepared and analyzed to determine NF-{kappa}B DNA binding activity. As shown in Fig. 6A, a complex was induced in MKN45 and MKN28 cells within 10 min after infection with H. pylori. This binding activity was reduced by addition of either cold probe or the typical NF-{kappa}B sequence derived from the IL-2R{alpha} enhancer but not by an oligonucleotide containing the AP-1 binding site (Fig. 6B, lanes 2 to 4). Next, we characterized the H. pylori-induced complexes identified by the CCL20 NF-{kappa}B probe. These complexes were supershifted by addition of anti-p50 or anti-p65 antibody (Fig. 6B, lanes 5 to 9), suggesting that H. pylori-induced CCL20 NF-{kappa}B complexes are composed of p50 and p65. Based on these results, H. pylori infection seems to induce CCL20 gene expression at least in part through induced binding of p50 and p65 to the NF-{kappa}B site in the CCL20 promoter region.


Figure 6
View larger version (67K):
[in this window]
[in a new window]

  		FIG. 6. H. pylori infection induced NF-{kappa}B binding activity. (A) Time course of NF-{kappa}B activation in MKN45 and MKN28 cells infected with H. pylori, evaluated by EMSA. Nuclear extracts from cells infected with H. pylori ATCC 49503 for the indicated times were mixed with 32P-labeled NF-{kappa}B probe. The bacterium-to-cell ratio was 20:1. (B) Sequence specificity of NF-{kappa}B binding activity and characterization of NF-{kappa}B proteins that bound to the NF-{kappa}B binding site of the CCL20 gene. Competition assays were performed with nuclear extracts from MKN45 and MKN28 cells infected with H. pylori ATCC 49503 for 1 h. Where indicated, 100-fold excess amounts of each specific competitor oligonucleotide were added to the reaction mixture with labeled probe NF-{kappa}B (lanes 2 to 4). A supershift assay of NF-{kappa}B DNA binding complexes in the same nuclear extracts was also performed. Where indicated, appropriate antibodies (Ab) were added to the reaction mixture before addition of the 32P-labeled probe (lanes 5 to 9). The arrows indicate the specific complexes, while the arrowheads indicate the DNA binding complexes supershifted by antibodies. (C) cag PAI products of H. pylori are required for induction of NF-{kappa}B binding activity in MKN45 cells. Nuclear extracts from MKN45 cells cocultured with different densities of wild-type strain 26695 or the isogenic mutant {Delta}cag PAI were analyzed for NF-{kappa}B. Representative results of three similar experiments in each panel are shown. WT, wild type.

 
As described above, cag PAI-positive strains induced significantly more CCL20 mRNA than cag PAI-negative H. pylori strains. Next, we determined whether cag PAI-positive H. pylori strains induced NF-{kappa}B better. Markedly increased NF-{kappa}B DNA binding activity was induced by wild-type strain 26695 compared with the activity induced by the isogenic cag PAI mutant (Fig. 6C). These results indicate that better activation of NF-{kappa}B binding by cag PAI-positive strains is the underlying mechanism for the observed activation of the CCL20 promoter by these bacterial strains. Considered together, these results indicate that H. pylori infection induces CCL20 gene expression at least in part through the induced binding of p50 and p65 NF-{kappa}B family members to the NF-{kappa}B element of the CCL20 promoter and that this effect is dependent on cag PAI products.

NF-{kappa}B signal is essential for induction of CCL20 expression by H. pylori. We next examined whether H. pylori-mediated upregulation of CCL20 gene expression involves signal transduction components in NF-{kappa}B activation. The activation of NF-{kappa}B requires phosphorylation of two conserved serine residues of I{kappa}B{alpha} (Ser-32 and Ser-36) and I{kappa}Bß (Ser-19 and Ser-23) within the NH2-terminal domain (31). Phosphorylation leads to ubiquitination and the 26S proteasome-mediated degradation of I{kappa}Bs, thereby releasing NF-{kappa}B from the complex to translocate to the nucleus and activate genes. The signal is eventually terminated through cytoplasmic resequestration of NF-{kappa}B, which depends on I{kappa}B{alpha} synthesis, a process requiring NF-{kappa}B transcriptional activity (31). H. pylori infection induced the phosphorylated I{kappa}B{alpha}. Kinetic analysis of H. pylori-induced degradation and resynthesis of I{kappa}B{alpha} in MKN45 cells revealed gradual replacement of I{kappa}B{alpha} levels (Fig. 7A). The high-molecular-weight IKK complex, which is composed of the two catalytic subunits (IKK{alpha} and IKKß) and the regulatory subunit (IKK{gamma}), phosphorylates I{kappa}Bs (31). Previous studies indicated that members of the mitogen-activated protein kinase kinase kinase family mediate physiologic activation of IKK (57). These kinases include NIK (54). I{kappa}B{alpha}, I{kappa}Bß, and IKK{gamma} dominant interfering mutants and IKK{alpha}, IKKß, and NIK kinase-deficient mutants were tested to determine their abilities to inhibit H. pylori-mediated activation of the CCL20-driven reporter gene. Expression of these various inhibitory mutants abolished H. pylori-induced CCL20 expression (Fig. 7B). These data show that signaling components involved in the activation of NF-{kappa}B are necessary for H. pylori activation of the CCL20 promoter.


Figure 7
View larger version (31K):
[in this window]
[in a new window]

  		FIG. 7. NF-{kappa}B signal is essential for activation of CCL20 expression by H. pylori. (A) H. pylori infection leads to I{kappa}B{alpha} phosphorylation and degradation. MKN45 cells were infected with H. pylori ATCC 49503 for the indicated times. The bacterium-to-cell ratio was 20:1. The cells were then lysed and analyzed by immunoblotting with phospho-specific I{kappa}B{alpha}, I{kappa}B{alpha}, and actin antibodies. Representative results of three similar experiments are shown. (B) Functional effects of I{kappa}B{alpha}, I{kappa}Bß, and IKK{gamma} dominant interfering mutants and kinase-deficient IKK{alpha}, IKKß, and NIK mutants on H. pylori-induced activation of the CCL20 promoter. MKN45 cells were transfected with pGL2-CCL20 and the indicated mutant plasmids or empty vector (pCMV4) and then infected with H. pylori ATCC 49503 for 6 h. The open bar indicates the luciferase activity of pGL2-CCL20 and pCMV4 without H. pylori infection. All values were first calculated as fold induction values relative to the basal level measured in uninfected cells. The data are means ± standard deviations of three independent experiments. (C) Bay 11-7082 and LLnL inhibit CCL20 mRNA expression induced by H. pylori. MKN45 cells were pretreated with Bay 11-7082 (20 µM) and LLnL (20 µM) for 1 h prior to H. pylori infection. They were subsequently infected with H. pylori for 6 h. CCL20 mRNA expression on harvested cells was analyzed by RT-PCR. Representative results of three similar experiments are shown. (D) Bay 11-7082 and LLnL inhibit H. pylori-induced NF-{kappa}B DNA binding. MKN45 cells were pretreated with Bay 11-7082 (20 µM) and LLnL (20 µM) for 1 h prior to H. pylori infection. They were subsequently infected with H. pylori for 1 h. Nuclear extracts from harvested cells were analyzed for NF-{kappa}B. Representative results of three similar experiments are shown.

 
Because activation of the CCL20 promoter by H. pylori infection required activation of NF-{kappa}B, we blocked NF-{kappa}B activation with Bay 11-7082, an inhibitor of I{kappa}B{alpha} phosphorylation (44), or LLnL, a proteasome inhibitor (28). This proteasome inhibitor is known to inhibit the activation of NF-{kappa}B by blocking the degradation of the I{kappa}B{alpha} protein. These studies demonstrated that there is a link between NF-{kappa}B activation and upregulation of CCL20 expression in H. pylori-infected cells. As shown in Fig. 7C, Bay 11-7082 or LLnL markedly inhibited H. pylori-induced expression of CCL20 mRNA. Bay 11-7082 or LLnL also inhibited H. pylori-induced NF-{kappa}B DNA binding (Fig. 7D).

Inhibition of Hsp90 reduces CCL20 expression induced by H. pylori. Hsp90 plays a critical role in the inflammatory response, and a requirement for Hsp90 for activation of NF-{kappa}B has been suggested (6, 7, 59). As a possible mechanistic link between H. pylori infection and inflammation, we hypothesized that Hsp90 is involved. To test this hypothesis, we investigated the effect of H. pylori infection on Hsp90 and evaluated the effect of the Hsp90 inhibitor 17-AAG on H. pylori-induced CCL20 expression. MKN45 cells constitutively expressed Hsp90 protein, but H. pylori infection did not affect its expression (Fig. 8A). Furthermore, pretreatment with 17-AAG completely inhibited H. pylori-induced CCL20 expression (Fig. 8B). These findings suggest that Hsp90 may be involved in H. pylori-induced CCL20 signaling.


Figure 8
View larger version (68K):
[in this window]
[in a new window]

  		FIG. 8. Inhibitory effects of 17-AAG on H. pylori-induced CCL20 expression. (A) H. pylori infection does not affect Hsp90 expression. MKN45 cells were infected with H. pylori ATCC 49503 for the indicated times. The bacterium-to-cell ratio was 20:1. The cells were then lysed and analyzed by immunoblotting with Hsp90 and actin antibodies. (B) MKN45 cells were incubated with 1 µM 17-AAG for 16 h prior to infection with different densities of H. pylori for 6 h. RT-PCR was performed to check the changes in CCL20 mRNA expression after 17-AAG treatment in H. pylori-infected MKN45 cells. (C) Attenuation of H. pylori-induced NF-{kappa}B DNA binding by 17-AAG treatment. MKN45 cells were treated (+) or not treated (–) with 17-AAG for 16 h prior to infection with H. pylori for 1 h. The nuclear extracts were isolated from MKN45 cells infected with H. pylori and analyzed for NF-{kappa}B. (D) Hsp90 protects IKK{alpha} and IKKß from proteasomal degradation. MKN45 cells either were pretreated with the proteasomal inhibitor LLnL (20 µM) for 1 h, followed or not followed by addition of 17-AAG (1 µM) and incubation for 16 h, or were treated with 17-AAG for 16 h or left untreated in the absence of H. pylori as indicated. Samples were analyzed for each protein by Western blotting. Representative results of three similar experiments are shown in each panel.

 
Next, we tested the direct influence of 17-AAG on H. pylori-induced transcriptional activity of NF-{kappa}B using EMSA. Pretreatment with 17-AAG decreased the retardation of gel mobility through inhibition of the DNA binding activity of the NF-{kappa}B complex, indicating that there was repression of the transcriptional activity of NF-{kappa}B (Fig. 8C). Of note, no differences in binding to the octamer motif on DNA were noted in the absence or presence of 17-AAG. Next, we examined the effect of 17-AAG on expression of IKK{alpha} and IKKß since IKK{alpha} and IKKß are known clients of Hsp90 (6). Treatment of MKN45 cells with 17-AAG in the absence of H. pylori reduced the amounts of the IKK{alpha} and IKKß proteins but not the amounts of IKK{gamma} and Hsp90 (Fig. 8D).

Several Hsp90 client proteins are degraded by the proteasome following Hsp90 inhibition (36). To examine whether proteasomal degradation was responsible for decreased levels of client proteins after 17-AAG treatment, MKN45 cells were cultured in a medium containing 17-AAG and the proteasomal inhibitor LLnL. 17-AAG-mediated degradation of IKK{alpha} and IKKß proteins was partially blocked by LLnL (Fig. 8D). In contrast, IKK{gamma} and Hsp90 were not destabilized by 17-AAG, and LLnL did not change the levels of IKK{gamma} and Hsp90. The reversal of 17-AAG-induced degradation of the IKK{alpha} and IKKß proteins by LLnL suggests that these proteins are subject to ubiquitin-dependent turnover.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
A recent study reported that H. pylori infection upregulated CCL20 expression in gastric epithelial cells and induced an influx of myeloid DCs in the lamina propria of the gastric mucosa in neonatally thymectomized mice (42). However, CCL20 expression in humans with H. pylori-induced gastritis remains unclear. We demonstrated here that there is upregulation of CCL20 mRNA expression in patients with H. pylori-infected gastritis compared with normal controls. Immunohistochemical analysis showed that CCL20 protein expression is localized exclusively in the mucosal epithelium. After completion of this work, Wu et al. reported that there was significantly increased CCR6 expression in CD3+ T cells infiltrating the gastric mucosa and that the ligand CCL20 was selectively expressed in inflamed gastric tissues from H. pylori-infected subjects (55). In the present study, we examined the hypothesis that H. pylori infection of gastric epithelial cells modulates the host cell CCL20 expression levels. Coculture with H. pylori significantly enhanced steady-state levels of CCL20 mRNA in gastric epithelial cells. The results showed that the NF-{kappa}B binding site present in the CCL20 promoter is required for CCL20 induction by H. pylori. However, mutagenesis of the NF-{kappa}B binding site did not reduce H. pylori-induced CCL20 promoter activation to baseline levels, suggesting that additional pathways are involved in stimulating CCL20 expression. The CCL20 promoter region contains a putative TATA and CAAT box and possible binding sites for various transcription factors other than NF-{kappa}B, like AP-1, AP-2, CAAT/enhancer-binding protein, Sp1, and the epithelium-specific Ets nuclear factor ESE-1 (48). The NF-{kappa}B binding site and to a lesser degree the AP-1 binding site are involved in H. pylori-induced IL-8 gene activation (1). Therefore, the AP-1 binding site may also be involved in H. pylori-induced CCL20 gene activation.

Because neither supernatants of H. pylori cultures nor H. pylori separated by a permeable membrane induced CCL20 expression, components of the H. pylori bacterium most likely trigger the induction of CCL20 in gastric cells. The finding that a cag PAI-negative strain of H. pylori could not induce CCL20 expression suggests that the cag PAI gene products are involved in the induction of CCL20 gene expression. In this study, we analyzed the capacities of different H. pylori strains to induce CCL20 and identified the signaling components NIK and IKKs as likely participants in H. pylori-mediated NF-{kappa}B activation. Compared with the cag PAI-negative H. pylori strain, the more virulent cag PAI-positive strains potently induced CCL20 promoter activity and NF-{kappa}B binding activity. This was consistent with our observations that increased induction of CCL20 in MKN45 cells was associated with cag PAI-positive strains. These results show that the cag PAI-positive H. pylori-induced CCL20 expression is dependent on prior activation of NF-{kappa}B p50 and p65 subunits. The cagE, cagG, and cagP genes or surrounding genes in the cag PAI have a function related to adhesion to epithelial cells (39, 58). However, the isogenic cag PAI mutant adhered a little less than the wild-type strain (26695) to MKN45 cells, suggesting that the reduced induction of CCL20 expression by the cag PAI mutant was not due to the reduced adherence to epithelial cells.

The mammalian signaling pathway(s) triggered by H. pylori remains largely unknown. In this study, we identified the cellular kinases NIK and IKKs as participants in NF-{kappa}B-dependent CCL20 induction by H. pylori in gastric epithelial cells. In addition, we documented the effect of the Hsp90 inhibitor 17-AAG on H. pylori-induced CCL20 expression and identified its molecular mechanism. 17-AAG inhibited CCL20 mRNA expression in H. pylori-infected gastric epithelial cells. This inhibition may have been due to inactivation of NF-{kappa}B signaling induced by H. pylori infection. Hsp90 is a regulator of NF-{kappa}B signaling through its general involvement in IKK activation (6). 17-AAG decreased the IKK complex proteins IKK{alpha} and IKKß. The loss of IKK reduced NF-{kappa}B DNA binding, resulting in a reduction in H. pylori-induced CCL20 mRNA expression. In agreement with our results, previous studies have shown that blockage of Hsp90 inhibits H. pylori-induced IL-8 production through the inactivation of NF-{kappa}B (56).

In conclusion, we obtained evidence of upregulated CCL20 expression in H. pylori-infected human gastric epithelial cells. Because CCL20 is important in the migration of myeloid DCs into the lamina propria of the gastric mucosa (42), modification of CCL20/CCR6 might be a potentially useful strategy in the pharmacological management of H. pylori-induced gastritis.


   ACKNOWLEDGMENTS
 
We thank T. Kitahora for providing clinical isolates of H. pylori; T. Hirayama for providing H. pylori strain ATCC 49503; C. Sasakawa for providing an H. pylori mutant lacking the cag PAI and its parental wild-type strain (26695); J. Fujisawa for providing reporter plasmid {kappa}B-LUC; D. W. Ballard for providing the I{kappa}B{alpha} and I{kappa}Bß dominant negative mutants; R. Geleziunas for providing the NIK, IKK{alpha}, and IKKß dominant negative mutants; and K.-T. Jeang for providing the IKK{gamma} dominant negative mutant.

This study was supported in part by Grant-in-Aid for Scientific Research (C) 19591123 to N.M. from Japan Society for the Promotion of Science and the Takeda Science Foundation.


   FOOTNOTES
 
* Corresponding author. Mailing address: Division of Molecular Virology and Oncology, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan. Phone: 81-98-895-1130. Fax: 81-98-895-1410. E-mail: n-mori{at}med.u-ryukyu.ac.jp Back

{triangledown} Published ahead of print on 27 August 2007. Back

Editor: A. Camilli


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
1. Aihara, M., D. Tsuchimoto, H. Takizawa, A. Azuma, H. Wakebe, Y. Ohmoto, K. Imagawa, M. Kikuchi, N. Mukaida, and K. Matsushima. 1997. Mechanisms involved in Helicobacter pylori-induced interleukin-8 production by a gastric cancer cell line, MKN45. Infect. Immun. 65:3218-3224.[Abstract]
2. Baggiolini, M., and P. Loetscher. 2000. Chemokines in inflammation and immunity. Immunol. Today 21:418-420.[CrossRef][Medline]
3. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245-252.[CrossRef][Medline]
4. Blaser, M. J., G. I. Perez-Perez, H. Kleanthous, T. L. Cover, R. M. Peek, P. H. Chyou, G. N. Stemmermann, and A. Nomura. 1995. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 55:2111-2115.[Abstract/Free Full Text]
5. Brockman, J. A., D. C. Scherer, T. A. McKinsey, S. M. Hall, X. Qi, W. Y. Lee, and D. W. Ballard. 1995. Coupling of a signal response domain in I{kappa}B{alpha} to multiple pathways for NF-{kappa}B activation. Mol. Cell. Biol. 15:2809-2818.[Abstract]
6. Broemer, M., D. Krappmann, and C. Scheidereit. 2004. Requirement of Hsp90 activity for I{kappa}B kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-{kappa}B activation. Oncogene 23:5378-5386.[CrossRef][Medline]
7. Byrd, C. A., W. Bornmann, H. Erdjument-Bromage, P. Tempst, N. Pavletich, N. Rosen, C. F. Nathan, and A. Ding. 1999. Heat shock protein 90 mediates macrophage activation by Taxol and bacterial lipopolysaccharide. Proc. Natl. Acad. Sci. USA 96:5645-5650.[Abstract/Free Full Text]
8. Campbell, J. J., G. Haraldsen, J. Pan, J. Rottman, S. Qin, P. Ponath, D. P. Andrew, R. Warnke, N. Ruffing, N. Kassam, L. Wu, and E. C. Butcher. 1999. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 400:776-780.[CrossRef][Medline]
9. Campbell, J. J., J. Hedrick, A. Zlotnik, M. A. Siani, D. A. Thompson, and E. C. Butcher. 1998. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 279:381-384.[Abstract/Free Full Text]
10. Censini, S., C. Lange, Z. Xiang, J. E. Crabtree, P. Ghiara, M. Borodovski, R. Rappuoli, and A. Covacci. 1996. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc. Natl. Acad. Sci. USA 93:14648-14653.[Abstract/Free Full Text]
11. Cook, D. N., D. M. Prosser, R. Forster, J. Zhang, N. A. Kuklin, S. J. Abbondanzo, X.-D. Niu, S.-C. Chen, D. J. Manfra, M. T. Wiekowski, L. M. Sullivan, S. R. Smith, H. B. Greenberg, S. K. Narula, M. Lipp, and S. A. Lira. 2000. CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity 12:495-503.[CrossRef][Medline]
12. Covacci, A., J. L. Telford, G. Del Giudice, J. Parsonnet, and R. Rappuoli. 1999. Helicobacter pylori virulence and genetic geography. Science 284:1328-1333.[Abstract/Free Full Text]
13. Crabtree, J. E., J. D. Taylor, J. I. Wyatt, R. V. Heatley, T. M. Shallcross, D. S. Tompkins, and B. J. Rathbone. 1991. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet 338:332-335.[CrossRef][Medline]
14. D'Elios, M. M., M. Manghetti, M. De Carli, F. Costa, C. T. Baldari, D. Burroni, J. L. Telford, S. Romagnani, and G. Del Prete. 1997. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J. Immunol. 158:962-967.[Abstract]
15. Dieu-Nosjean, M.-C., A. Vicari, S. Lebecque, and C. Caux. 1999. Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. J. Leukoc. Biol. 66:252-262.[Abstract]
16. Dieu-Nosjean, M.-C., C. Massacrier, B. Homey, B. Vanbervliet, J.-J. Pin, A. Vicari, S. Lebecque, C. Dezutter-Dambuyant, D. Schmitt, A. Zlotnik, and C. Caux. 2000. Macrophage inflammatory protein 3{alpha} is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J. Exp. Med. 192:705-718.[Abstract/Free Full Text]
17. Fitzhugh, D. J., S. Naik, S. W. Caughman, and S. T. Hwang. 2000. C-C chemokine receptor 6 is essential for arrest of a subset of memory T cells on activated dermal microvascular endothelial cells under physiologic flow conditions in vitro. J. Immunol. 165:6677-6681.[Abstract/Free Full Text]
18. Foryst-Ludwig, A., and M. Naumann. 2000. p21-activated kinase 1 activates the nuclear factor {kappa}B (NF-{kappa}B)-inducing kinase-I{kappa}B kinases NF-{kappa}B pathway and proinflammatory cytokines in Helicobacter pylori infection. J. Biol. Chem. 275:39779-39785.[Abstract/Free Full Text]
19. Geleziunas, R., S. Ferrell, X. Lin, Y. Mu, E. T. Cunningham, Jr., M. Grant, M. A. Connelly, J. E. Hambor, K. B. Marcu, and W. C. Greene. 1998. Human T-cell leukemia virus type 1 Tax induction of NF-{kappa}B involves activation of the I{kappa}B kinase {alpha} (IKK{alpha}) and IKKß cellular kinases. Mol. Cell. Biol. 18:5157-5165.[Abstract/Free Full Text]
20. Hafsi, N., P. Voland, S. Schwendy, R. Rad, W. Reindl, M. Gerhard, and C. Prinz. 2004. Human dendritic cells respond to Helicobacter pylori, promoting NK cell and Th1-effector responses in vitro. J. Immunol. 173:1249-1257.[Abstract/Free Full Text]
21. Hieshima, K., T. Imai, G. Opdenakker, J. Van Damme, J. Kusuda, H. Tei, Y. Sakaki, K. Takatsuki, R. Miura, O. Yoshie, and H. Nomiyama. 1997. Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. J. Biol. Chem. 272:5846-5853.[Abstract/Free Full Text]
22. Hocker, M., and P. Hohenberger. 2003. Helicobacter pylori virulence factors—one part of a big picture. Lancet 362:1231-1233.[CrossRef][Medline]
23. Houghton, J., and T. C. Wang. 2005. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. Gastroenterology 128:1567-1578.[CrossRef][Medline]
24. Hromas, R., P. W. Gray, D. Chantry, R. Godiska, M. Krathwohl, K. Fife, G. I. Bell, J. Takeda, S. Aronica, M. Gordon, S. Cooper, H. E. Broxmeyer, and M. J. Klemsz. 1997. Cloning and characterization of exodus, a novel ß-chemokine. Blood 89:3315-3322.[Abstract/Free Full Text]
25. Iha, H., K. V. Kibler, V. R. Yedavalli, J. M. Peloponese, K. Haller, A. Miyazato, T. Kasai, and K.-T. Jeang. 2003. Segregation of NF-{kappa}B activation through NEMO/IKK{gamma} by Tax and TNF{alpha}: implications for stimulus-specific interruption of oncogenic signaling. Oncogene 22:8912-8923.[CrossRef][Medline]
26. Imaizumi, Y., S. Sugita, K. Yamamoto, D. Imanishi, T. Kohno, M. Tomonaga, and T. Matsuyama. 2002. Human T cell leukemia virus type-I Tax activates human macrophage inflammatory protein-3{alpha}/CCL20 gene transcription via the NF-{kappa}B pathway. Int. Immunol. 14:147-155.[Abstract/Free Full Text]
27. Iwasaki, A., and B. L. Kelsall. 2000. Localization of distinct Peyer's patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3{alpha}, MIP-3ß, and secondary lymphoid organ chemokine. J. Exp. Med. 191:1381-1394.[Abstract/Free Full Text]
28. Jeremias, I., C. Kupatt, B. Baumann, I. Herr, T. Wirth, and K. M. Debatin. 1998. Inhibition of nuclear factor {kappa}B activation attenuates apoptosis resistance in lymphoid cells. Blood 91:4624-4631.[Abstract/Free Full Text]
29. Johansson-Lindbom, B., and W. W. Agace. 2007. Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol. Rev. 215:226-242.[CrossRef][Medline]
30. Kao, J. Y., S. Rathinavelu, K. A. Eaton, L. Bai, Y. Zavros, M. Takami, A. Pierzchala, and J. L. Merchant. 2006. Helicobacter pylori-secreted factors inhibit dendritic cell IL-12 secretion: a mechanism of ineffective host defense. Am. J. Physiol. Gastrointest. Liver Physiol. 291:G73-G81.[Abstract/Free Full Text]
31. Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-{kappa}B activity. Annu. Rev. Immunol. 18:621-663.[CrossRef][Medline]
32. Karttunen, R., T. Karttunen, H. P. Ekre, and T. T. MacDonald. 1995. Interferon {gamma} and interleukin 4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. Gut 36:341-345.[Abstract/Free Full Text]
33. Kranzer, K., L. Sollner, M. Aigner, N. Lehn, L. Deml, M. Rehli, and W. Schneider-Brachert. 2005. Impact of Helicobacter pylori virulence factors and compounds on activation and maturation of human dendritic cells. Infect. Immun. 73:4180-4189.[Abstract/Free Full Text]
34. Liao, F., R. L. Rabin, C. S. Smith, G. Sharma, T. B. Nutman, and J. M. Farber. 1999. CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3{alpha}. J. Immunol. 162:186-194.[Abstract/Free Full Text]
35. Maeda, S., H. Yoshida, K. Ogura, Y. Mitsuno, Y. Hirata, Y. Yamaji, M. Akanuma, Y. Shiratori, and M. Omata. 2000. H. pylori activates NF-{kappa}B through a signaling pathway involving I{kappa}B kinases, NF-{kappa}B-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells. Gastroenterology 119:97-108.[CrossRef][Medline]
36. Maloney, A., and P. Workman. 2002. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2:3-24.[CrossRef][Medline]
37. Mantovani, A. 1999. The chemokine system: redundancy for robust outputs. Immunol. Today 20:254-257.[CrossRef][Medline]
38. McKinsey, T. A., J. A. Brockman, D. C. Scherer, S. W. Al-Murrani, P. L. Green, and D. W. Ballard. 1996. Inactivation of I{kappa}Bß by the Tax protein of human T-cell leukemia virus type 1: a potential mechanism for constitutive induction of NF-{kappa}B. Mol. Cell. Biol. 16:2083-2090.[Abstract]
39. Mizushima, T., T. Sugiyama, T. Kobayashi, Y. Komatsu, J. Ishizuka, M. Kato, and M. Asaka. 2002. Decreased adherence of cagG-deleted Helicobacter pylori to gastric epithelial cells in Japanese clinical isolates. Helicobacter 7:22-29.[CrossRef][Medline]
40. Mori, N., M. Fujii, S. Ikeda, Y. Yamada, M. Tomonaga, D. W. Ballard, and N. Yamamoto. 1999. Constitutive activation of NF-{kappa}B in primary adult T-cell leukemia cells. Blood 93:2360-2368.[Abstract/Free Full Text]
41. Moss, S. F., and S. Sood. 2003. Helicobacter pylori. Curr. Opin. Infect. Dis. 16:445-451.[CrossRef][Medline]
42. Nishi, T., K. Okazaki, K. Kawasaki, T. Fukui, H. Tamaki, M. Matsuura, M. Asada, T. Watanabe, K. Uchida, N. Watanabe, H. Nakase, M. Ohana, H. Hiai, and T. Chiba. 2003. Involvement of myeloid dendritic cells in the development of gastric secondary lymphoid follicles in Helicobacter pylori-infected neonatally thymectomized BALB/c mice. Infect. Immun. 71:2153-2162.[Abstract/Free Full Text]
43. Peek R. M., Jr., and M. J. Blaser. 2002. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat. Rev. Cancer 2:28-37.[CrossRef][Medline]
44. Pierce, J. W., R. Schoenleber, G. Jesmok, J. Best, S. A. Moore, T. Collins, and M. E. Gerritsen. 1997. Novel inhibitors of cytokine-induced I{kappa}B{alpha} phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 272:21096-21103.[Abstract/Free Full Text]
45. Richter, K., and J. Buchner. 2001. Hsp90: chaperoning signal transduction. J. Cell. Physiol. 188:281-290.[CrossRef][Medline]
46. Robinson, K., R. H. Argent, and J. C. Atherton. 2007. The inflammatory and immune response to Helicobacter pylori infection. Best Pract. Res. Clin. Gastroenterol. 21:237-259.[CrossRef][Medline]
47. Rossi, D. L., A. P. Vicari, K. Franz-Bacon, T. K. McClanahan, and A. Zlotnik. 1997. Identification through bioinformatics of two new macrophage proinflammatory human chemokines: MIP-3{alpha} and MIP-3ß. J. Immunol. 158:1033-1036.[Abstract]
48. Schutyser, E., S. Struyf, and J. Van Damme. 2003. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 14:409-426.[CrossRef][Medline]
49. Sharma, S. A., M. K. Tummuru, M. J. Blaser, and L. D. Kerr. 1998. Activation of IL-8 gene expression by Helicobacter pylori is regulated by transcription factor nuclear factor-{kappa}B in gastric epithelial cells. J. Immunol. 160:2401-2407.[Abstract/Free Full Text]
50. Suerbaum, S., and P. Michetti. 2002. Helicobacter pylori infection. N. Engl. J. Med. 347:1175-1186.[Free Full Text]
51. Tanaka, J., T. Suzuki, H. Mimuro, and C. Sasakawa. 2003. Structural definition on the surface of Helicobacter pylori type IV secretion apparatus. Cell. Microbiol. 5:395-404.[CrossRef][Medline]
52. Tummuru, M. K. R., S. A. Sharma, and M. J. Blaser. 1995. Helicobacter pylori picB, a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL-8 in gastric epithelial cells. Mol. Microbiol. 18:867-876.[CrossRef][Medline]
53. Wada, A., N. Mori, K. Oishi, H. Hojo, Y. Nakahara, Y. Hamanaka, M. Nagashima, I. Sekine, K. Ogushi, T. Niidome, T. Nagatake, J. Moss, and T. Hirayama. 1999. Induction of human ß-defensin-2 mRNA expression by Helicobacter pylori in human gastric cell line MKN45 cells on cag pathogenicity island. Biochem. Biophys. Res. Commun. 263:770-774.[CrossRef][Medline]
54. Woronicz, J. D., X. Gao, Z. Cao, M. Rothe, and D. V. Goeddel. 1997. I{kappa}B kinase-ß: NF-{kappa}B activation and complex formation with I{kappa}B kinase-{alpha} and NIK. Science 278:866-869.[Abstract/Free Full Text]
55. Wu, Y.-Y., H.-F. Tsai, W.-C. Lin, P.-I. Hsu, C.-T. Shun, M.-S. Wu, and P.-N. Hsu. 2007. Upregulation of CCL20 and recruitment of CCR6+ gastric infiltrating lymphocytes in Helicobacter gastritis. Infect. Immun. 75:4357-4363.[Abstract/Free Full Text]
56. Yeo, M., H.-K. Park, K.-M. Lee, K. J. Lee, J. H. Kim, S. W. Cho, and K.-B. Hahm. 2004. Blockage of HSP 90 modulates Helicobacter pylori-induced IL-8 production through the inactivation of transcriptional factors of AP-1 and NF-{kappa}B. Biochem. Biop